• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖胺聚糖抑制生物体液中LL-37的抗菌活性。

Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids.

作者信息

Barańska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A

机构信息

Department of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Debinki 7 Street, 80-288 Gdańsk, Poland.

出版信息

J Antimicrob Chemother. 2006 Feb;57(2):260-5. doi: 10.1093/jac/dki460. Epub 2005 Dec 30.

DOI:10.1093/jac/dki460
PMID:16387752
Abstract

OBJECTIVES

The antibacterial activity of antimicrobial peptides is influenced by various factors such as salt content, pH and the presence of proteins. In this study, we explored the antibacterial action of the human cathelicidin LL-37 in physiologically relevant conditions, i.e. various human wound fluids, human plasma fractions and serum.

METHODS

Radial diffusion assays using Staphylococcus aureus and Escherichia coli were employed for the study of antibacterial effects of LL-37 in the presence of 12 different wound fluids, citrate-, heparin- or EDTA-plasma, or human serum. Glycosaminoglycan content of wound fluids was determined by an Alcian Blue-binding assay. Protein content of wound fluids was measured by the Bradford method. A slot-binding assay was used to study the effects of inhibitors on the interaction between LL-37 and glycosaminoglycans.

RESULTS

Five of twelve wound fluids derived from acute wounds showed marked inhibitory effects on the antibacterial action of LL-37. The inhibition was significantly correlated with high glycosaminoglycan content in wound fluid. Analogous to these findings, heparin-plasma strongly inhibited the antibacterial effect of LL-37. The interaction between LL-37 and glycosaminoglycans was abrogated by the cationic polymers DEAE-dextran and chitosan, yielding increased activity of LL-37.

CONCLUSIONS

Glycosaminoglycan-rich biological fluids inhibit the antibacterial effects of LL-37. Furthermore, polycations that bind to glycosaminoglycans increase the antibacterial activities of endogenous antimicrobial peptides in glycosaminoglycan-containing biological fluids.

摘要

目的

抗菌肽的抗菌活性受多种因素影响,如盐含量、pH值和蛋白质的存在。在本研究中,我们探讨了人cathelicidin LL-37在生理相关条件下,即各种人伤口液、人血浆组分和血清中的抗菌作用。

方法

采用金黄色葡萄球菌和大肠杆菌的径向扩散试验,研究LL-37在12种不同伤口液、柠檬酸盐、肝素或乙二胺四乙酸血浆或人血清存在下的抗菌效果。通过阿尔辛蓝结合试验测定伤口液中的糖胺聚糖含量。采用Bradford法测定伤口液中的蛋白质含量。采用狭缝结合试验研究抑制剂对LL-37与糖胺聚糖相互作用的影响。

结果

来自急性伤口的12种伤口液中有5种对LL-37的抗菌作用表现出明显的抑制作用。这种抑制作用与伤口液中高糖胺聚糖含量显著相关。与这些发现类似,肝素血浆强烈抑制LL-37的抗菌作用。阳离子聚合物DEAE-葡聚糖和壳聚糖消除了LL-37与糖胺聚糖之间的相互作用,使LL-37的活性增加。

结论

富含糖胺聚糖的生物流体抑制LL-37的抗菌作用。此外,与糖胺聚糖结合的聚阳离子可增加含糖胺聚糖生物流体中内源性抗菌肽的抗菌活性。

相似文献

1
Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids.糖胺聚糖抑制生物体液中LL-37的抗菌活性。
J Antimicrob Chemother. 2006 Feb;57(2):260-5. doi: 10.1093/jac/dki460. Epub 2005 Dec 30.
2
Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13.唾液黏蛋白可抑制由cathelicidin衍生的LL-37肽的抗菌活性,但对阳离子类固醇CSA-13没有抑制作用。
J Antimicrob Chemother. 2008 Aug;62(2):329-35. doi: 10.1093/jac/dkn176. Epub 2008 May 1.
3
Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli.抗菌剂人β-防御素、杀菌肽LL-37和溶菌酶对金黄色葡萄球菌和大肠杆菌的协同作用。
J Dermatol Sci. 2005 Nov;40(2):123-32. doi: 10.1016/j.jdermsci.2005.03.014. Epub 2005 Jun 15.
4
Synergistic actions of antibacterial neutrophil defensins and cathelicidins.抗菌中性粒细胞防御素和cathelicidin的协同作用。
Inflamm Res. 2000 Feb;49(2):73-9. doi: 10.1007/s000110050561.
5
Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma.脓毒症休克期间糖胺聚糖水平升高:与死亡率及血浆抗菌作用的关系
Shock. 2008 Dec;30(6):623-7. doi: 10.1097/SHK.0b013e3181777da3.
6
The fabrication and in vitro properties of antibacterial polydopamine-LL-37-POPC coatings on micro-arc oxidized titanium.微弧氧化钛表面抗菌聚多巴胺-LL-37-POPC 涂层的制备及体外性能
Colloids Surf B Biointerfaces. 2018 Oct 1;170:54-63. doi: 10.1016/j.colsurfb.2018.05.070. Epub 2018 May 31.
7
Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37.人源杀菌肽LL-37类似物的抗菌和趋化活性、脂多糖中和作用、细胞毒性及血清抑制作用
Antimicrob Agents Chemother. 2005 Jul;49(7):2845-50. doi: 10.1128/AAC.49.7.2845-2850.2005.
8
LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline.在囊性纤维化肺中,LL-37与糖胺聚糖的络合会抑制抗菌活性,而高渗盐水可恢复这种活性。
J Immunol. 2009 Jul 1;183(1):543-51. doi: 10.4049/jimmunol.0803959.
9
Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus.具有抗金黄色葡萄球菌抗菌和抗生物膜活性的天然和合成抗菌肽。
BMC Microbiol. 2011 May 23;11:114. doi: 10.1186/1471-2180-11-114.
10
Modulation of exogenous antibiotic activity by host cathelicidin LL-37.宿主防御肽 LL-37 对外源抗生素活性的调节作用。
APMIS. 2010 Nov;118(11):830-6. doi: 10.1111/j.1600-0463.2010.02667.x. Epub 2010 Sep 14.

引用本文的文献

1
Cathelicidins: Opportunities and Challenges in Skin Therapeutics and Clinical Translation.Cathelicidins:皮肤治疗与临床转化中的机遇与挑战
Antibiotics (Basel). 2024 Dec 24;14(1):1. doi: 10.3390/antibiotics14010001.
2
Molecular Mechanisms of Bacterial Resistance to Antimicrobial Peptides in the Modern Era: An Updated Review.现代细菌对抗菌肽耐药性的分子机制:最新综述
Microorganisms. 2024 Jun 21;12(7):1259. doi: 10.3390/microorganisms12071259.
3
Greater mechanistic understanding of the cutaneous pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review.
深入了解史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症的皮肤发病机制可以为新的治疗策略提供启示:全面综述。
Curr Opin Allergy Clin Immunol. 2024 Aug 1;24(4):218-227. doi: 10.1097/ACI.0000000000000993. Epub 2024 May 17.
4
LL37 Microspheres Loaded on Activated Carbon-chitosan Hydrogel: Anti-bacterial and Anti-toxin Wound Dressing for Chronic Wound Infections.载 LL37 微球的活性炭-壳聚糖水凝胶:用于慢性伤口感染的抗菌、抗毒伤口敷料。
AAPS PharmSciTech. 2024 May 13;25(5):110. doi: 10.1208/s12249-024-02826-6.
5
Bacterial pneumonia-induced shedding of epithelial heparan sulfate inhibits the bactericidal activity of cathelicidin in a murine model.细菌肺炎诱导的上皮细胞肝素硫酸盐释放抑制了抗菌肽在小鼠模型中的杀菌活性。
Am J Physiol Lung Cell Mol Physiol. 2024 Feb 1;326(2):L206-L212. doi: 10.1152/ajplung.00178.2023. Epub 2023 Dec 19.
6
Between good and evil: Complexation of the human cathelicidin LL-37 with nucleic acids.善恶之间:人源抗菌肽 LL-37 与核酸的复合物形成
Biophys J. 2024 Jun 4;123(11):1316-1328. doi: 10.1016/j.bpj.2023.10.035. Epub 2023 Nov 2.
7
Antimicrobial Peptides-Mechanisms of Action, Antimicrobial Effects and Clinical Applications.抗菌肽——作用机制、抗菌效果及临床应用
Antibiotics (Basel). 2022 Oct 16;11(10):1417. doi: 10.3390/antibiotics11101417.
8
Glycosaminoglycan, Antimicrobial Defence Molecule and Cytokine Appearance in Tracheal Hyaline Cartilage of Healthy Humans.健康人体气管透明软骨中糖胺聚糖、抗菌防御分子及细胞因子的表现
J Funct Morphol Kinesiol. 2022 Jul 21;7(3):55. doi: 10.3390/jfmk7030055.
9
Host-Bacterial Interactions: Outcomes of Antimicrobial Peptide Applications.宿主-细菌相互作用:抗菌肽应用的结果
Membranes (Basel). 2022 Jul 19;12(7):715. doi: 10.3390/membranes12070715.
10
Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model.抗菌肽LL-37在耐甲氧西林金黄色葡萄球菌伤口感染小鼠模型中的疗效
Antibiotics (Basel). 2021 Oct 5;10(10):1210. doi: 10.3390/antibiotics10101210.